Souhaitez-vous accéder aux communiqués récents ?

SYDNEY, Australia, July 15, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) announces the grant of patent no. 10,711,060 entitled “Antibody molecules...

Completes recruitment of patients with first line Non-Small Cell Lung Cancer (NSCLC)81 patients out of up to 109 now participating across the trial, with recruitment continuing for Part B and stage 2...

SYDNEY, Australia, June 22, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,437,826 cash rebate from...

Presented at ASCO 2020 Annual Meeting First complete response reported in 2nd line head and neck squamous cell carcinoma (HNSCC)Improving Overall Response Rate (iORR) in HNSCC, increasing to 38.9%...

First data from this collaboration study with Merck KGaA, Darmstadt, Germany, and Pfizer Inc and sponsor, IKF, presented at ASCOEncouraging early activity signals in a variety of cancer...

SYDNEY, Australia, May 29, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for...

SYDNEY, Australia, May 27, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) will host a global webcast on Tuesday 2 June 2020 at 7.30am, Australia Eastern Standard Time (AEST) /...

SYDNEY, Australia, April 30, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce new data are scheduled to be presented in two...

Increasing benefit reported from patients with first line Non-Small Cell Lung Cancer (NSCLC):    º Improving Overall Response Rate (ORR) of 53% (earlier data indicated 47%)    º Improving Progression...

SYDNEY, Australia, April 22, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...